4YB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Minimal LeverageMinimal leverage reduces refinancing and interest-rate risk, while substantial equity and assets provide financial flexibility to fund clinical development and absorb setbacks without immediate dependence on debt markets.
Settlement Materially Strengthens LiquidityThe settlement provides a substantial liquidity buffer that can support multiple clinical programs, regulatory activities and commercialization investment, extending operational flexibility while reducing near-term financing dependence.
Broad Pipeline With Multiple Development And Launch CatalystsA diversified pipeline and recurring clinical milestones create multiple opportunities to convert research investment into approved products and revenue, reducing reliance on any single indication over the medium term.
Bears Say
Pre-revenue Business ModelThe absence of commercial product revenue leaves the company dependent on clinical success, regulatory approvals and external funding sources, limiting earnings visibility until launches generate sustainable product sales.
Very High And Increasing Cash BurnLarge operating cash outflows and worsening burn increase the resources required to sustain development. Even with strong liquidity, prolonged spending could reduce financial flexibility before commercial revenues scale.
Clinical Execution And Trial-power RiskVariability in placebo response, patient populations and disease biology can weaken statistical power or limit data interpretation, creating durable risk to approval timelines, pipeline value and future commercialization plans.
Immunovant News
4YB FAQ
What was Immunovant’s price range in the past 12 months?
Currently, no data Available
What is Immunovant’s market cap?
Immunovant’s market cap is €7.78B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Oct 30, 2026 which is in 63 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 06, 2026. The company reported -€0.643 earnings per share for the quarter, missing the consensus estimate of -€0.539 by -€0.104.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.63.
How many shares outstanding does Immunovant have?
Currently, no data Available
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -€0.643 in its last earnings report, missing expectations of -€0.539. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in DE:4YB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€42.63 (― Upside)
€42.63 (― Upside)
Blogger Sentiment
Bullish
DE:4YB Sentiment 71%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €10.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.88%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
4YB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial near-term and medium-term upside: a large multipart settlement that materially increases liquidity, an active and well-funded pipeline with multiple imminent readouts and a potential approval/launch for brexpiprazole in dermatomyositis, successful enrollments in registrational studies, and ongoing shareholder capital returns. These positives were balanced against recognized clinical and operational risks—placebo variability, translation risk for PH-ILD, JAK-class safety perceptions, geographic variability in trials, and continued high R&D and G&A spend. On balance, management presents confident execution and a strong catalyst calendar that outweigh the disclosed risks.View all DE:4YB earnings summaries4YB Stock 12 Month Forecast
Average Price Target
―TG Therapeutics
―
Viridian Therapeutics
―
Aurinia Pharmaceuticals
―
Protagonist Therapeutics
―
Kymera Therapeutics
―